Summary. Seven adult patients with myelodysplastic syndrome (MDS)-related secondary acute myeloid leukaemia (AML) were treated with total body irradiation (TBI), cytosine arabinoside (Ara-C) and cyclophosphamide (CY), followed by unrelated human leucocyte antigen (HLA)-mismatched cord blood transplantation (CBT). Granulocyte colony-stimulating factor (G-CSF) was infused continuously from 12 h before until the end of Ara-C therapy to enhance the antileukaemia effect of Ara-C. Five patients are alive and free of disease at 7±31 months after transplantation. These preliminary results suggest that adult MDS-related secondary AML patients without suitable related or unrelated bone marrow donors should be considered as candidates for CBT.
The prognosis of myelodysplastic syndrome (MDS)-related secondary acute myeloid leukaemia (AML) is poor. Although some patients with MDS-related secondary AML achieve remission with standard remission induction chemotherapy, the duration is usually short (de Witte et al, 1995) . Therefore, allogeneic stem cell transplantation is considered to be the only curative treatment choice for MDSrelated secondary AML patients (Anderson et al, 1996 (Anderson et al, , 1997 Runde et al, 1998; Okamoto et al, 1999; de Witte et al, 2000) . Recently, alternative donor sources other than human leucocyte antigen (HLA)-identical siblings have been used as allogeneic stem cell sources (Anderson et al, 1996 (Anderson et al, , 1997 de Witte et al, 2000) . Here, we report our clinical experience with adult patients with MDS-related secondary AML treated with unrelated cord blood transplantation (CBT).
PATIENTS AND METHODS
Patients. Between August 1998 and August 2000, seven adult patients with MDS-related secondary AML were treated with unrelated CBT at The Research Hospital, The Institute of Medical Science, University of Tokyo. MDSrelated secondary AML was defined as AML which developed during the follow-up period of MDS, morphologically diagnosed according to the French±American± British (FAB) Cooperative Group criteria. Among the seven patients, four did not receive any induction therapy before transplantation. The other three patients received induction therapy and could not achieve complete remission. Therefore, all patients received CBT as an up-front treatment not a post-remission consolidation. Among the patients the median age was 38 years (range, 20±50 years), the median weight was 51 kg (range, 43±63 kg) and the median number of infused nucleated cells was 2´18 Â 10 7 /kg (range, 2´09±4´06 Â 10 7 /kg). Although it is difficult to obtain a large number of cord blood nucleated cells for adult patients, it was shown that the number of infused cells was associated with the probability of engraftment after CBT (Gluckman et al, 1997; Rubinstein et al, 1998; Gluckman, 2000) . In addition, a relationship between the time to neutrophil and platelet recovery and HLA compatibility has been documented (Gluckman et al, 1997; Rubinstein et al, 1998; Gluckman, 2000) . Therefore, cord blood units were selected according to the number of nucleated cells per recipient's weight and HLA compatibility (HLA-A and B by serology and HLA-DRB1 DNA typing). The characteristics of the seven patients and cord blood units are shown in Table I . Two patients included in our previous studies were also included (UPN305, UPN314) (Nagayama et al, 1999; Machida et al 2000) . No patients had a related or unrelated bone marrow donor available at the time of transplantation. Informed consent for treatment was obtained from all patients.
Transplant procedure. All patients received three to four fractionated 12 Gy total body irradiation ( and then every other day because they were participating in a randomized, prospective study.
RESULTS AND DISCUSSION
All patients had myeloid reconstitution and the median time to . 0´5 Â 10 9 /l absolute neutrophil count was 24 d (range, 19±35 d). A self-sustained platelet count greater than 50 Â 10 9 /l was achieved in six patients at a median time of 49 d (range, 35±164 d). Acute GVHD occurred in five out of seven patients and chronic GVHD in four out of six evaluable patients. Two patients died of relapse on d 107 and 307, and five patients are alive and free of disease between 7 and 31 months after transplantation (Table II) . Among the five patients who are alive and free of disease, four had not received any induction therapy before transplantation.
Although allogeneic stem cell transplantation from an HLA-identical related donor offers a potential cure for MDSrelated secondary AML patients, a suitably matched related donor is unavailable for approximately two-thirds of patients. Recently, results of transplantation from unrelated bone marrow donors have been reported (Anderson et al, 1996) . As non-relapse mortality was higher in patients who received transplants from HLA-identical unrelated bone marrow donors than from HLA-identical related donors, Anderson et al (1997) suggested that the outcome after transplantation for MDS-related secondary AML may be improved by transplanting as soon as possible after the diagnosis of AML in an attempt to reduce toxicity. Although the patients required early transplantation, none of our patients had any related or unrelated bone marrow donors and unrelated cord blood was used as an alternative stem cell source. The long-term disease-free survival (DFS) rate for MDS-related secondary AML patients receiving allogeneic stem cell transplantation is approximately 30% (Anderson et al, 1997; Runde et al, 1998; de Witte et al, 2000) and high relapse rates may result in a poor rate of DFS. Our previous experience suggested that a G-CSFcombined preparative regimen was capable of reducing the post-transplant relapse rate in refractory myeloid malignancies (Takahashi et al, 1994; Okamoto et al, 1999) ; thus, G-CSF and Ara-C were combined with a standard TBI and CY regimen to reduce the incidence of relapse. Although the relatively small number of patients studied do not permit firm conclusions concerning the relative effectiveness of the preparative regimens and the usefulness of unrelated cord blood as an alternative stem cell source, our preliminary results suggest that adult MDS-related secondary AML patients without suitable related or unrelated bone marrow donors should be considered as candidates for CBT.
